← Leaderboards
Haitao Guo
Baruch S. Blumberg Institute
$14,400,355
Attributed
$17,433,473
Total exposure
16
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,433,473 · 16
By mechanism
R01$13,672,078 · 6
R21$1,707,406 · 4
R56$1,490,470 · 2
R41$320,863 · 1
P30$237,656 · 2
R13$5,000 · 1
Top collaborators
- Andrea Cuconati6 shared
- Zandrea Ambrose2 shared
- Zhongde Wang2 shared
- Heidi A Kay1 shared
- Daryl T Lau1 shared
- Ying-Hsiu Su1 shared
Most similar at Baruch S. Blumberg Institute
Same institution · by research overlap
- Ying-Hsiu Su$4,579,119
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralHepatitis B VirusVirus DiseasesPharmaceutical PreparationsVirusChronic Hepatitis BCellsAffectResponseChronicVirus ReplicationCircular DnaPathway InteractionsProteinsAntiviral AgentsLongevityInfectionHepatocyteCell LineAnalogGenetic TranscriptionPolymeraseViral GenomeLead
Grant awards (53)
Development of a hamster model for hepatitis B virus infection$728,653
R01 · FY2025 · AI
The Role of HBeAg in HBV Persistence$511,721
R01 · FY2025 · AI · contact PI
Molecular Mechanisms of HBV cccDNA Formation$387,255
R01 · FY2025 · AI · contact PI
Translational Development of a Small Molecule for the Treatment of HBV Infection$320,863
R41 · FY2025 · AI
High throughput screening and preclinical development of HBV cccDNA inhibitors$227,642
R21 · FY2025 · AI · contact PI
Cancer Virology Program$45,251
P30 · FY2025 · CA · contact PI
Development of a hamster model for hepatitis B virus infection$756,589
R01 · FY2024 · AI
Molecular Mechanisms of HBV cccDNA Formation$387,554
R01 · FY2024 · AI · contact PI
Epigenetic Regulation of HBV cccDNA Transcription$387,255
R01 · FY2024 · AI · contact PI
High throughput screening and preclinical development of HBV cccDNA inhibitors$198,750
R21 · FY2024 · AI · contact PI
Cancer Virology Program$39,496
P30 · FY2024 · CA · contact PI
HBV cccDNA and integrated DNA in HIV coinfection and HBV monoinfection$847,428
R56 · FY2023 · AI
Molecular Mechanisms of HBV cccDNA Formation$387,843
R01 · FY2023 · AI · contact PI
Epigenetic Regulation of HBV cccDNA Transcription$387,554
R01 · FY2023 · AI · contact PI
Cancer Virology Program$39,496
P30 · FY2023 · CA · contact PI
Molecular Mechanisms of HBV cccDNA Formation$388,124
R01 · FY2022 · AI · contact PI
Epigenetic Regulation of HBV cccDNA Transcription$387,357
R01 · FY2022 · AI · contact PI
Pathogenesis of HIV and HBV Co-Infection in a Humanized Mouse Model$236,313
R21 · FY2022 · OD
Cancer Virology Program$39,496
P30 · FY2022 · CA · contact PI
The Role of HBeAg in HBV Persistence$395,844
R01 · FY2021 · AI · contact PI
Epigenetic Regulation of HBV cccDNA Transcription$389,570
R01 · FY2021 · AI · contact PI
Molecular Mechanisms of HBV cccDNA Formation$382,533
R01 · FY2021 · AI · contact PI
Pathogenesis of HIV and HBV Co-Infection in a Humanized Mouse Model$195,625
R21 · FY2021 · OD
Cancer Virology Program$35,042
P30 · FY2021 · CA · contact PI
The Role of HBeAg in HBV Persistence$410,693
R01 · FY2020 · AI · contact PI
Epigenetic Regulation of HBV cccDNA Transcription$403,923
R01 · FY2020 · AI · contact PI
Cancer Virology Program$38,875
P30 · FY2020 · CA · contact PI
Molecular Mechanisms of HBV cccDNA Formation$362,512
R01 · FY2019 · AI · contact PI
The Role of HBeAg in HBV Persistence$358,864
R01 · FY2019 · AI · contact PI
Development of an HTS Assay for Discovery of HBV cccDNA Inhibitors$314,216
R01 · FY2019 · AI · contact PI
Development of an HTS Assay for Discovery of HBV cccDNA Inhibitors$78,034
R01 · FY2019 · AI · contact PI
The Role of HBeAg in HBV Persistence$42,490
R01 · FY2019 · AI · contact PI
Molecular Mechanisms of HBV cccDNA Formation$16,506
R01 · FY2019 · AI · contact PI
The Role of HBeAg in HBV Persistence$418,840
R01 · FY2018 · AI · contact PI
Molecular Mechanisms of HBV cccDNA Formation$393,750
R01 · FY2018 · AI · contact PI
Development of an HTS Assay for Discovery of HBV cccDNA Inhibitors$392,250
R01 · FY2018 · AI · contact PI
Development of an HTS Assay for Discovery of HBV cccDNA Inhibitors$404,744
R01 · FY2017 · AI · contact PI
Molecular Mechanisms of HBV cccDNA Formation$392,500
R01 · FY2017 · AI · contact PI
Molecular Mechanisms of HBV cccDNA Formation$381,600
R01 · FY2016 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$686,525
R01 · FY2015 · AI · contact PI
Molecular Mechanisms of ZAP/ISG20 mediated HBV RNA Decay$195,000
R21 · FY2015 · AI · contact PI
2015 International Meeting on the Molecular Biology of Hepatitis B Viruses$5,000
R13 · FY2015 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$681,531
R01 · FY2014 · AI · contact PI
Molecular Mechanisms of ZAP/ISG20 mediated HBV RNA Decay$234,000
R21 · FY2014 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$1
R01 · FY2014 · AI · contact PI
Molecular Mechanisms of ZAP/ISG20 mediated HBV RNA Decay$1
R21 · FY2014 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$603,728
R01 · FY2013 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$627,419
R01 · FY2012 · AI · contact PI
Development of a novel drug candidate that inhibits hepatitis B virus covalently$824,100
R01 · FY2011 · AI · contact PI
Molecular mechanism of innate immunity control of HBV replication$190,575
R21 · FY2011 · AI · contact PI
Molecular mechanism of innate immunity control of HBV replication$229,500
R21 · FY2010 · AI · contact PI
Screen for an unexploited step in the HBV life cycle$305,542
R56 · FY2009 · AI
Screen for an unexploited step in the HBV life cycle$337,500
R56 · FY2008 · AI